Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Stone

Showing results (121-130 of 420) with videos related to

Pageof 42
Sort By:
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Cancer|August 9, 2020
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromesCharlotte K Brierley, Emily C Zabor, Rami S Komrokji, et al.
Leukemia|March 28, 2024
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patientsShai Shimony, Jacqueline S Garcia, Julia Keating, et al.
Blood Advances|January 4, 2018
Systematic <i>STAT3</i> sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemiaElizabeth A Morgan, Mark N Lee, Daniel J DeAngelo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseDaniel J DeAngelo, Ephraim P Hochberg, Edwin P Alyea, et al.
Molecular Cancer Therapeutics|January 18, 2014
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2Suhu Liu, Sarah R Walker, Erik A Nelson, et al.
Leukemia & Lymphoma|February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Journal of Neuropathology and Experimental Neurology|July 31, 2018
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral EdemaMatthew Torre, Isaac H Solomon, Claire L Sutherland, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 29, 2007
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantationPhilippe Armand, Haesook T Kim, Daniel J DeAngelo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2010
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromesPeter L Greenberg, Cynthia K Rigsby, Richard M Stone, et al.
Pageof 42

Showing results (121-130 of 420) with videos related to

Sort By:
Pageof 42
Leukemia Research|August 7, 2010
High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902Richard M Stone, Barry Moser, Ben Sanford, et al.
Cancer|August 9, 2020
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromesCharlotte K Brierley, Emily C Zabor, Rami S Komrokji, et al.
Leukemia|March 28, 2024
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patientsShai Shimony, Jacqueline S Garcia, Julia Keating, et al.
Blood Advances|January 4, 2018
Systematic <i>STAT3</i> sequencing in patients with unexplained cytopenias identifies unsuspected large granular lymphocytic leukemiaElizabeth A Morgan, Mark N Lee, Daniel J DeAngelo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host diseaseDaniel J DeAngelo, Ephraim P Hochberg, Edwin P Alyea, et al.
Molecular Cancer Therapeutics|January 18, 2014
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2Suhu Liu, Sarah R Walker, Erik A Nelson, et al.
Leukemia & Lymphoma|February 20, 2016
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665Rebecca DeBoer, Gregory Koval, Flora Mulkey, et al.
Journal of Neuropathology and Experimental Neurology|July 31, 2018
Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral EdemaMatthew Torre, Isaac H Solomon, Claire L Sutherland, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 29, 2007
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantationPhilippe Armand, Haesook T Kim, Daniel J DeAngelo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2010
NCCN Task Force: Transfusion and iron overload in patients with myelodysplastic syndromesPeter L Greenberg, Cynthia K Rigsby, Richard M Stone, et al.
Pageof 42